For following the competition: what moved in each program, several studies read as one move.
- Octreotide Sustained-release Formulation Debio 4126
- afabicin
- Anti-CD37/DM1 Derivative Antibody-drug Conjugate Debio 1562M
- + 1 more
Mondays · ranked, phase 3 first · readouts ahead · See a sample brief
Add Debiopharm to watchlistEvery Monday by email · turn it off any timePro · free during the beta